User profiles for Glenn D. Crater
 | Glenn CraterClinical Pharma Specialist Consultants, LLC Verified email at clinicalpharmaspecialist.com Cited by 2748 |
[HTML][HTML] Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD
NA Hanania, GD Crater, AN Morris, AH Emmett… - Respiratory …, 2012 - Elsevier
BACKGROUND: Combining maintenance medications with different mechanisms of action
may improve outcomes in COPD. In this study we evaluated the efficacy and safety of …
may improve outcomes in COPD. In this study we evaluated the efficacy and safety of …
Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol
…, FM Wigley, KM Kral, IH Raphiou, GD Crater - The Journal of …, 2009 - jrheum.org
Objective. Pulmonary arterial hypertension (PAH) remains challenging to treat, especially in
association with scleroderma. We examined survival rates among patients with PAH in …
association with scleroderma. We examined survival rates among patients with PAH in …
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19
Severe coronavirus disease 2019 (COVID-19) is characterised by pneumonia with excessive
systemic inflammation, referred to as a “cytokine storm” [1–3]. Dexamethasone treatment …
systemic inflammation, referred to as a “cytokine storm” [1–3]. Dexamethasone treatment …
[HTML][HTML] Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD
…, DB Rubin, AH Emmett, MJ Cicale, GD Crater… - Respiratory …, 2011 - Elsevier
BACKGROUND: COPD is associated with increased arterial stiffness which may in part
explain the cardiovascular morbidity observed in the disease. A causal relationship between …
explain the cardiovascular morbidity observed in the disease. A causal relationship between …
Effects of CB1R inverse agonist, INV‐202, in patients with features of metabolic syndrome. A randomized, placebo‐controlled, double‐blind phase 1b study
GD Crater, K Lalonde, F Ravenelle… - Diabetes, Obesity …, 2024 - Wiley Online Library
Aims To evaluate the clinical safety, tolerability, and pharmacokinetic and pharmacodynamic
profile of the novel cannabinoid receptor‐1 (CB1R) inverse agonist, INV‐202, in adults with …
profile of the novel cannabinoid receptor‐1 (CB1R) inverse agonist, INV‐202, in adults with …
[HTML][HTML] Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial
…, BM Jean-Francois, AF Preece, J Blowers, GD Crater… - PLoS …, 2012 - journals.plos.org
Umeclidinium bromide (GSK573719; UMEC), a new long-acting muscarinic receptor antagonist
(LAMA), is in development with vilanterol (GW642444; VI), a selective long-acting β 2 …
(LAMA), is in development with vilanterol (GW642444; VI), a selective long-acting β 2 …
Prevalence of airway obstruction assessed by lung function questionnaire
…, AA Dalal, IH Raphiou, BA Prillaman, GD Crater… - Mayo Clinic …, 2011 - Elsevier
OBJECTIVE To estimate the prevalence of unidentified chronic obstructive pulmonary disease
(COPD) and determine the screening accuracy of the Lung Function Questionnaire (LFQ). …
(COPD) and determine the screening accuracy of the Lung Function Questionnaire (LFQ). …
[HTML][HTML] Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation
JA Ohar, GD Crater, A Emmett, TJ Ferro, AN Morris… - Respiratory …, 2014 - Springer
Background Inhaled long-acting beta 2 agonists used alone and in combination with an
inhaled corticosteroid reduce the risk of exacerbations in patients with stable COPD. However, …
inhaled corticosteroid reduce the risk of exacerbations in patients with stable COPD. However, …
[HTML][HTML] Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD
Background There are limited data describing patients with moderate COPD exacerbations
and evaluating comparative effectiveness of maintenance treatments in this patient …
and evaluating comparative effectiveness of maintenance treatments in this patient …
[HTML][HTML] Peak inspiratory flows: defining repeatability limits and a predictive equation for different inhalers
…, DA Mahler, JA Ohar, DA Lombardi, GD Crater - Chest, 2020 - Elsevier
Background Peak inspiratory flow (PIF) has been proposed as a measure to assess a patient’s
ability to use dry powder inhalers (DPIs). However, robust quality criteria to determine a …
ability to use dry powder inhalers (DPIs). However, robust quality criteria to determine a …